KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Prepaid Assets (2020 - 2025)

Recursion Pharmaceuticals' Prepaid Assets history spans 6 years, with the latest figure at $11.7 million for Q4 2025.

  • For Q4 2025, Prepaid Assets fell 60.33% year-over-year to $11.7 million; the TTM value through Dec 2025 reached $11.7 million, down 60.33%, while the annual FY2025 figure was $11.7 million, 60.33% down from the prior year.
  • Prepaid Assets reached $11.7 million in Q4 2025 per RXRX's latest filing, down from $37.3 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $43.7 million in Q2 2024 to a low of $2.6 million in Q1 2021.
  • Average Prepaid Assets over 5 years is $21.9 million, with a median of $17.0 million recorded in 2022.
  • Peak YoY movement for Prepaid Assets: soared 488.78% in 2022, then plummeted 60.33% in 2025.
  • A 5-year view of Prepaid Assets shows it stood at $7.5 million in 2021, then skyrocketed by 111.19% to $15.9 million in 2022, then soared by 153.62% to $40.2 million in 2023, then decreased by 26.45% to $29.6 million in 2024, then tumbled by 60.33% to $11.7 million in 2025.
  • Per Business Quant, the three most recent readings for RXRX's Prepaid Assets are $11.7 million (Q4 2025), $37.3 million (Q2 2025), and $32.0 million (Q1 2025).